Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
24 hedge funds and large institutions have $10.4M invested in Astria Therapeutics in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
4% more funds holding
Funds holding: 23 → 24 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6.07% less ownership
Funds ownership: 38.99% → 32.92% (-6.1%)
11% less capital invested
Capital invested by funds: $11.8M → $10.4M (-$1.35M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$267K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$89.3K |
| 3 |
Renaissance Technologies
New York
|
+$67.1K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$46.5K |
| 5 |
OC
Oppenheimer & Co
New York
|
+$41.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$183K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$162K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$139K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$45K |
| 5 |
Goldman Sachs
New York
|
-$31K |
ATXS Hedge Fund Activity: Q2 2017 in Review
24 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2017, worth a combined $10.4M — down 11% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ATXS positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $267K. The largest seller was Vanguard Group, cutting an estimated $183K.
- 24 institutional investors held Astria Therapeutics (ATXS) as of Q2 2017, up from 23 in Q1 2017.
- Funds reported $10.4M of Astria Therapeutics stock for Q2 2017, down 11% quarter-over-quarter.
- 5 funds opened new Astria Therapeutics positions in Q2 2017 and 4 closed out, a net change of +1 holder.
- The largest Astria Therapeutics buyer in Q2 2017 was Virtu KCG Holdings, an estimated $267K added.
- The largest Astria Therapeutics seller in Q2 2017 was Vanguard Group, an estimated $183K sold.
Based on aggregated 13F filings for Q2 2017.